JT
ITCI

Jump Trading’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jump Trading’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14,600
Closed -$178K – 606
2019
Q1 		$178K Buy
+14,600
New +$187K 0.06% 403

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Jump Trading's ITCI Position: Q2 2019 in Review

Jump Trading sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2019, closing a stake of 14,600 shares — an estimated $178K sold.

Jump Trading first reported a position in ITCI in Q1 2019 and held it in 1 quarter. The position peaked at $178K in Q1 2019. 126 funds tracked by Wall St. Rank hold ITCI as of Q2 2019.

  • Jump Trading reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2019 after selling out during the quarter.
  • Jump Trading sold 14,600 Intra-Cellular Therapies Inc. shares in Q2 2019, an estimated $178K.
  • Jump Trading first reported a position in Intra-Cellular Therapies Inc. in Q1 2019 and held it in 1 quarter.
  • Jump Trading's Intra-Cellular Therapies Inc. position peaked at $178K in Q1 2019.
  • 126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2019.

Based on Jump Trading's 13F filing for Q2 2019, filed 14 Aug 2019.